Group 1 - Shanghai Weike Biotechnology Co., Ltd. completed A-round financing of nearly 100 million RMB, with investors including Shenzhen Capital Group and Xichuang Investment [1][2] - The company was established on March 8, 2021, and is a leading innovative enterprise in the field of gene therapy safety evaluation, focusing on integrated viral insertion site analysis (ISA) [2] - Weike Biotechnology specializes in risk assessment of insertion mutations in gene therapy, high-precision CRISPR/Cas9 off-target analysis, vector copy number (VCN), vector quality control, immune repertoire analysis, and efficient sgRNA screening [2] Group 2 - The company provides comprehensive customized services from sample reception to report submission, including sample quality control, library preparation, next-generation sequencing, bioinformatics analysis, and ISA risk assessment reports [2] - Current clients include nearly 20 universities, hospitals, and biotechnology companies, such as Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine and Legend Biotech [2]